2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. CNS Infection

CNS Infection

Central nervous system infections involve pathogens affecting the brain and spinal cord, presenting as encephalitis, meningitis, or brain abscesses, with increased risk in neutropenic patients and those with cerebrospinal fluid shunt implants.

 

CNS Infection (106):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N1423
    Glycocholic acid 475-31-0 99.90%
    Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
    Glycocholic acid
  • HY-B1659
    Glycerol 56-81-5 99.99%
    Glycerol is used in sample preparation and gel formation for polyacrylamide gel electrophoresis.
    Glycerol
  • HY-124617A
    AMXT-1501 tetrahydrochloride 2444815-84-1 98.0%
    AMXT-1501 tetrahydrochloride is a Bacterial agent and polyamine transport system inhibitor. AMXT-1501 tetrahydrochloride targets membrane phospholipids and exhibits antibacterial activity against a variety of Gram-positive and Gram-negative multidrug-resistant bacteria. AMXT-1501 tetrahydrochloride inhibits capsular biosynthesis in Streptococcus pneumoniae. AMXT-1501 tetrahydrochloride targets ornithine decarboxylase and polyamines to inhibit the proliferation of neuroblastoma cells. AMXT-1501 tetrahydrochloride in combination with DFMO (HY-B0744) induces Apoptosis in neuroblastoma cells. AMXT-1501 tetrahydrochloride is applicable to research related to multidrug-resistant bacterial infections, pneumococcal infections, Streptococcus pneumoniae infections, and neuroblastoma.
    AMXT-1501 tetrahydrochloride
  • HY-P99568
    Telitacicept 2136630-26-5 99.30%
    Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease. The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.
    Telitacicept
  • HY-Y0344D
    Sodium chloride, for cell culture 7647-14-5 99.9%
    Sodium chloride, for cell culture is an orally active salt. Sodium chloride, for cell culture induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, for cell culture enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, for cell culture drives autoimmune disease by the induction of pathogenic Th17 cells.
    Sodium chloride, for cell culture
  • HY-P11553A
    ECL1i TFA
    ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis.
    ECL1i TFA
  • HY-W017087
    1,2,4-Trimethoxybenzene 135-77-3
    1,2,4-Trimethoxybenzene is an orally active NLRP3 selective inhibitor. 1,2,4-Trimethoxybenzene can markedly suppress Nigericin (HY-127019) or ATP (HY-B2176)-induced NLRP3 inflammasome activation, thus decreasing caspase-1 activation and IL-1β secretion. 1,2,4-Trimethoxybenzene specifically inhibits the activation of NLRP3 inflammasome without affecting absent in melanoma 2 (AIM2) inflammasome activation. 1,2,4-Trimethoxybenzene inhibits oligomerization of the apoptosis-associated speck-like protein containing a CARD (ASC) and protein-protein interaction between NLRP3 and ASC, thus blocking NLRP3 inflammasome assembly. 1,2,4-Trimethoxybenzene can be used for the study of experimental autoimmune encephalomyelitis (EAE), multiple sclerosis, and type 2 diabetes.
    1,2,4-Trimethoxybenzene
  • HY-N19420
    Theasinensin C 89013-69-4
    Theasinensin C is an orally effective renin inhibitor and gut microbiota modulator, with an IC50 of 40.21 μM against renin activity. Theasinensin C selectively enriches Akkermansia muciniphila in the gut microbiota, enhances the Akkermansia muciniphila-mediated hydrolysis of the PTS domain of mucin, drives the accumulation of luminal glutamine and serine, and regulates the gut-kidney-liver glutamine/serine metabolic signaling pathway to promote creatine biosynthesis. Theasinensin C improves cognitive function, reduces pro-inflammatory cytokines, alleviates neuropathological changes and restores intestinal barrier integrity. Theasinensin C can be used in research related to hypertension and neuroinflammation induced by high-fructose diet.
    Theasinensin C
  • HY-N6810
    Thymol 89-83-8 99.97%
    Thymol is a TRPA1 agonist. Thymol induces cancer cell apoptosis. Thymol is the main monoterpene phenol occurring in essential oils isolated from plants belonging to the Lamiaceae family, and other plants such as those belonging to the Verbenaceae, Scrophulariaceae, Ranunculaceae and Apiaceae families. Thymol has antioxidant, anti-inflammatory, antibacterial and antifungal effects.
    Thymol
  • HY-B1005
    8-Hydroxyquinoline 148-24-3 99.99%
    8-Hydroxyquinoline (8-Quinolinol) is a lipophilic metal chelator that can be used as a fungicide .8-Hydroxyquinoline shows the MIC range of 27.56-55.11 μM (4-8 μg/mL) against the clinical isolates of Neisseria gonorrhoeae. 8-Hydroxyquinoline can bind to copper form complexes and transport copper into cells. 8-Hydroxyquinoline increases in the number of micronucleated polychromatic erythrocytes and can also make hair depigmented in mice.
    8-Hydroxyquinoline
  • HY-P990008
    Atrosab 1365659-05-7 99.94%
    Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Atrosab
  • HY-N0681
    D-Pantothenic acid hemicalcium salt 137-08-6 99.80%
    D-Pantothenic acid hemicalcium salt is an orally active vitamin that reduces patulin in apple juice. D-Pantothenic acid hemicalcium salt removes ROS. D-Pantothenic acid hemicalcium salt has antibacterial and immunomodulatory activities. D-Pantothenic acid hemicalcium salt also has the effect of improving osteoporosis and obesity.
    D-Pantothenic acid hemicalcium salt
  • HY-108831
    Natalizumab 189261-10-7 99.10%
    Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses.
    Natalizumab
  • HY-N0610
    Trans-Cinnamic acid 140-10-3 99.98%
    trans-Cinnamic acid is a natural antimicrobial, with minimal inhibitory concentration (MIC) of 250 μg/mL against fish pathogen A. sobria, SY-AS1.
    Trans-Cinnamic acid
  • HY-108831A
    Natalizumab (Anti-CD49d) 189261-10-7 99.71%
    Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses.
    Natalizumab (Anti-CD49d)
  • HY-P991049
    Atrosimab 99%
    Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis.
    Atrosimab
  • HY-P99148
    Anti-Mouse/Rat/Rabbit TNF alpha Antibody (TN3-19.12)
    Anti-Mouse TNF alpha Antibody (TN3-19.12) is an anti-mouse TNF alpha IgG antibody inhibitor derived from host Armenian Hamster. Anti-Mouse TNF alpha Antibody (TN3-19.12) neutralizes cytotoxic activity in supernatants obtained from LNC-8 cells. Anti-Mouse TNF alpha Antibody (TN3-19.12) reduces the symptoms and severity of EAE (experimental allergic encephalomyelitis) in LNC-8 cells xenograft mice models. Anti-Mouse TNF alpha Antibody (TN3-19.12) prevents diabetes in NOD mice. Anti-Mouse TNF alpha Antibody (TN3-19.12) shows apparent radiosensitizing effect in CD2F1 mice.
    Anti-Mouse/Rat/Rabbit TNF alpha Antibody (TN3-19.12)
  • HY-B0987
    Ascorbyl palmitate 137-66-6 99.62%
    Ascorbyl palmitate is an orally active ester formed from ascorbic acid and palmitic acid, used as an antioxidant and food additive. Ascorbyl palmitate in preventing fat and oil oxidation is more efficient than Butylated hydroxyanisole (HY-B1066) and Butylated hydroxytoluene (HY-Y0172). Ascorbyl palmitate mitigates inhibition of collagen synthesis by select calcium and sodium channel blockers. Ascorbyl palmitate induces Apoptosis in human umbilical vein endothelial cells (HUVECs). Ascorbyl palmitate ameliorates inflammatory diseases by inhibition of NLRP3 inflammasome.
    Ascorbyl palmitate
  • HY-109520
    Glatiramer acetate 147245-92-9 98.0%
    Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.
    Glatiramer acetate
  • HY-P990155
    Anti-Mouse TIGIT Antibody (1G9) 99.71%
    Anti-Mouse TIGIT Antibody (1G9) is a mouse-derived agonistic TIGIT IgG1 κ type antibody. Anti-Mouse TIGIT Antibody (1G9) blocks CD155 binding to TIGIT. Anti-Mouse TIGIT Antibody (1G9) shows potent anti-infection and anti-immune effects in septic and experimental autoimmune encephalomyelitis.
    Anti-Mouse TIGIT Antibody (1G9)